US Patent

US8153689 — Pleuromutilin derivatives for the treatment of diseases mediated by microbes

Composition of Matter · Assigned to Nabriva Therapeutics AG · Expires 2028-03-19 · 2y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects pleuromutilin derivatives, specifically those of formula (I), for the treatment of diseases caused by microbes.

USPTO Abstract

Disclosed are pleuromutilin derivatives of formula (I) and their use in the treatment of diseases mediated by microbes.

Drugs covered by this patent

lefamulin-acetate (LEFAMULIN ACETATE)

Patent Metadata

Patent number: US8153689
Jurisdiction: US
Classification: Composition of Matter
Expires: 2028-03-19
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Nabriva Therapeutics AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.